JCEM:阿片类药物及其对内分泌的影响

2019-09-14 xing.T MedSci原创

由此可见,男性阿片类药物使用者中有一半以上出现性腺功能减退,约占所有患者的五分之一。因此,建议对性腺和肾上腺轴进行定期评估。

阿片类药物使用的增加导致了前所未有的阿片类药物流行。慢性阿片类药物的使用导致性腺机能减退,但其频率以及阿片类药物对其他下丘脑-垂体-靶器官激素轴的影响仍不清楚。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该系统评价和荟萃分析的目的是评估阿片类药物使用对垂体功能的影响。

研究人员检索了八个电子数据库,查找了截至2018年5月8日发表的文献。研究人员进行固定或随机效应荟萃分析以估计合并比例以及95%置信区间。该研究报告遵循了PRISMA-和MOOSE-指南。

研究人员纳入了52研究(22低偏倚风险),共包含了18428名受试者,包括慢性疼痛患者(n=21项研究),或阿片类药物成瘾的维持治疗者( n=9)和健康志愿者(n=4)。最常用的阿片类药物是美沙酮(n=13项研究),其次是吗啡(n=12)。性腺机能减退的患病率为63%(95%CI为55-70%,15项研究,3250名患者,99.5%为男性)。依赖于动态和非动态测试的皮质醇分泌的患病率为15%(95%CI为6-28%,5项研究,205名患者,57.5%为男性),仅包括使用胰岛素耐量试验的研究患病率为24%(95%CI为16-33%,2项研究,n=97名患者)。7项研究中有5项研究纳入了高催乳素血症患者。未描述对生长激素和下丘脑-垂体-甲状腺轴的明显影响。

由此可见,男性阿片类药物使用者中有一半以上出现性腺功能减退,约占所有患者的五分之一。因此,建议对性腺和肾上腺轴进行定期评估。 

原始出处:

Friso de Vries,et al.Opioids and their endocrine effects: A systematic review and meta-analysis.J Clin Endocrinol Metab. 2019.https://doi.org/10.1210/clinem/dgz022

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1777883, encodeId=7e591e778836d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Oct 18 09:11:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063265, encodeId=4403206326596, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 07 20:11:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682559, encodeId=8dbf16825596d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Apr 18 03:11:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253096, encodeId=753312530962a, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309139, encodeId=686f13091392f, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-10-18 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1777883, encodeId=7e591e778836d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Oct 18 09:11:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063265, encodeId=4403206326596, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 07 20:11:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682559, encodeId=8dbf16825596d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Apr 18 03:11:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253096, encodeId=753312530962a, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309139, encodeId=686f13091392f, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-12-07 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1777883, encodeId=7e591e778836d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Oct 18 09:11:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063265, encodeId=4403206326596, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 07 20:11:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682559, encodeId=8dbf16825596d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Apr 18 03:11:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253096, encodeId=753312530962a, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309139, encodeId=686f13091392f, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-04-18 gwc392
  4. [GetPortalCommentsPageByObjectIdResponse(id=1777883, encodeId=7e591e778836d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Oct 18 09:11:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063265, encodeId=4403206326596, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 07 20:11:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682559, encodeId=8dbf16825596d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Apr 18 03:11:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253096, encodeId=753312530962a, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309139, encodeId=686f13091392f, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1777883, encodeId=7e591e778836d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Oct 18 09:11:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063265, encodeId=4403206326596, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 07 20:11:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682559, encodeId=8dbf16825596d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Apr 18 03:11:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253096, encodeId=753312530962a, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309139, encodeId=686f13091392f, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Sep 16 06:11:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 lhlxtx

相关资讯

Rizmoic获得欧洲委员会的营销许可,用于治疗阿片类药物引起的成人便秘

欧洲委员会(EC)近日批准了Rizmoic(naldemedine)的营销许可(MA),用于治疗先前接受过泻药治疗的阿片类药物引起的成人便秘(OIC)。EC对naldemedine的批准是基于三项III期有效性和安全性研究(V9231,V9232和V9236)和一项长期安全性研究(V9235)的数据。

Ann Rheum Dis:与类风湿性关节炎患者骨折风险相关的药物

使用阿片类药物、SSRIs和糖皮质激素与RA患者的骨折风险增加相关,而他汀类药物和TNFi与椎骨骨折减少相关。

2019 SPA建议:儿童围手术期阿片类药物的应用

2019年3月,儿科麻醉学会(SPA)发布了儿童围手术期阿片类药物的应用建议。长期以来,阿片类药物在成人以及儿童围手术期疼痛的治疗中发挥着重要作用,本文主要针对儿童围手术期阿片类药物的应用提供指导建议,解决了术后儿童阿片类药物应用的重要问题,包括疼痛评估,阿片类药物治疗监测,药物应用策略以及镇痛效果评估等。

又一家药企深陷阿片类药物成瘾危机!或赔偿100-120亿美元

这两天,强生被裁定造成阿片类药物成瘾危机而被判赔5.7亿美元,这一事件在医药圈闹得沸沸扬扬。然而,深陷阿片成瘾危机的药企并非只有强生一家。普渡制药(Purdue Pharma)可能正在以100-120亿美元的价格解决数千起与阿片类药物成瘾危机有关的诉讼。

JAMA Netw Open:孕期滥用阿片类药物,或许带给孩子长期不良影响

目前,我们知道,如果孕妈妈在妊娠期滥用阿片类药物,如吗啡、海洛因、曲马多、羟考酮和美沙酮等,可能会导致婴儿早产或低出生体重的风险。

JCO:结直肠癌,肺癌和乳腺癌老年幸存者中阿片类药物使用的趋势

已有的研究显示,癌症幸存者可能会有阿片类药物相关危害增加的风险。但是,至今为止,自诊断以来患者使用阿片类药物的趋势未知。